Page contents Key factsDecisionRelated medicine informationKey facts Invented name Fasenra Active Substance Benralizumab Therapeutic area Dermatology Decision number P/0314/2020 PIP number EMEA-001214-PIP06-20 Pharmaceutical form(s) Age-appropriate dosage form for parenteral useSolution for injection Condition(s) / indication(s) Treatment of bullous pemphigoid Route(s) of administration Subcutaneous use Contact for public enquiries AstraZeneca ABE-mail: paediatrics@astrazeneca.comTel. +46 855326000 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 14/08/2020DecisionP/0314/2020 : EMA decision of 14 August 2020 on the granting of a product specific waiver for benralizumab (Fasenra) (EMEA-001214-PIP06-20)AdoptedReference Number: EMA/413751/2020 English (EN) (199.85 KB - PDF)First published: 18/06/2021ViewRelated medicine informationFasenraShare this page